Fortis Healthcare Ltd (Fortis) owns, operates, and manages multi-specialty hospitals and super-specialty centers. It offers an array of healthcare services, including Cardiac Sciences, Geriatric Medicine, Oncology, Neurology, Liver Transplant, and Hepatobiliary Sciences, among others.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D department undertakes clinical research studies, co-marketing projects, and co-development of new biomarkers and contract validations. The company focuses on diagnostic advancements, process efficiency, cutting-edge technologies, and futuristic areas such as genomics. Its major focus is to develop and launch multi-pathogen panels for syndromic testing of infectious diseases, oncology, and genetics. Fortis, through its subsidiary Agilus Diagnostics, has undertaken significant R&D initiatives in FY2025. The company expanded its focus on diagnostic advancements, process efficiency, high-end technologies, and emerging areas such as Genomics. Its major objectives included enhancing the esoteric test menu to cater to Pan India requests and introducing six new tests targeting seasonal infections and bacterial detection. The genomics portfolio was expanded with new multi-disorder panels, and point-of-care technology for emergency diagnostics was implemented. The company’s R&D efforts also explored contract evaluation services, co-marketing projects, and feasibility assessments for clinical research studies. Additionally, innovative method development for measuring growth biomarkers in hair specimens was completed. Agilus established a technology transfer agreement to bring advanced testing capabilities in-house and progressed toward registration as an Evaluation Center for Medical Devices and Diagnostics. Marketing campaign support was provided for the High-Risk HPV test launch and a new molecular TB test.